Patients with Inflammatory bowel disease (IBD) have shown, in several studies, a non-negligible risk of reduced quality of life and a significant prevalence of psychological and depressive disorders. It has often been pointed out that the family-social context of the patient also carries the burden of the disease (concerns about therapies and adverse effects, the need for surgery, rehabilitation prospects, etc.).
The COVID-19 pandemic has brought physicians face-to-face with the extra-pharmacological needs of these patients and the need to improve their quality of life because it has often been reported that increased stress is often the genesis of new disease relapses and thus of a worse course of the disease.
Our target is to respond to the issues, still the subject of scientific debate, on the 360-degree management of inflammatory bowel disease.
The main subjects will therefore be:
• New strategies for improving the quality of life of IBD patients.
• New evidence on the quality of life of patients with IBD.
• Non-pharmacological interventions to improve the burden of the disease on the patient's family members.
• New evidence on the relationship between quality of life and course of IBDs and emerging risk factors for disease relapse.
• New evidence on protective remission factors directly related to the quality of life of patients with IBD.
• Multidisciplinary management of IBDs and what we learned from the COVID-19 pandemic.
Patients with Inflammatory bowel disease (IBD) have shown, in several studies, a non-negligible risk of reduced quality of life and a significant prevalence of psychological and depressive disorders. It has often been pointed out that the family-social context of the patient also carries the burden of the disease (concerns about therapies and adverse effects, the need for surgery, rehabilitation prospects, etc.).
The COVID-19 pandemic has brought physicians face-to-face with the extra-pharmacological needs of these patients and the need to improve their quality of life because it has often been reported that increased stress is often the genesis of new disease relapses and thus of a worse course of the disease.
Our target is to respond to the issues, still the subject of scientific debate, on the 360-degree management of inflammatory bowel disease.
The main subjects will therefore be:
• New strategies for improving the quality of life of IBD patients.
• New evidence on the quality of life of patients with IBD.
• Non-pharmacological interventions to improve the burden of the disease on the patient's family members.
• New evidence on the relationship between quality of life and course of IBDs and emerging risk factors for disease relapse.
• New evidence on protective remission factors directly related to the quality of life of patients with IBD.
• Multidisciplinary management of IBDs and what we learned from the COVID-19 pandemic.
